Oncologists ||| S:0 E:11 ||| NNP
'  ||| S:11 E:13 ||| POS
experiences  ||| S:13 E:25 ||| NNS
with  ||| S:25 E:30 ||| IN
drug  ||| S:30 E:35 ||| NN
shortages  ||| S:35 E:45 ||| NNS
There  ||| S:45 E:51 ||| EX
have  ||| S:51 E:56 ||| VBP
been  ||| S:56 E:61 ||| VBN
numerous  ||| S:61 E:70 ||| JJ
reports  ||| S:70 E:78 ||| NNS
of  ||| S:78 E:81 ||| IN
shortages  ||| S:81 E:91 ||| NNS
of  ||| S:91 E:94 ||| IN
injectable  ||| S:94 E:105 ||| JJ
drugs  ||| S:105 E:111 ||| NNS
for  ||| S:111 E:115 ||| IN
cancer  ||| S:115 E:122 ||| NN
in  ||| S:122 E:125 ||| IN
the  ||| S:125 E:129 ||| DT
last  ||| S:129 E:134 ||| JJ
decade ||| S:134 E:140 ||| NN
.  ||| S:140 E:142 ||| .
We  ||| S:142 E:145 ||| PRP
assessed  ||| S:145 E:154 ||| VBD
physician  ||| S:154 E:164 ||| NN
experiences  ||| S:164 E:176 ||| NNS
with  ||| S:176 E:181 ||| IN
drug  ||| S:181 E:186 ||| NN
shortages  ||| S:186 E:196 ||| NNS
in  ||| S:196 E:199 ||| IN
a  ||| S:199 E:201 ||| DT
population-based  ||| S:201 E:218 ||| JJ
cohort  ||| S:218 E:225 ||| NN
of  ||| S:225 E:228 ||| IN
medical  ||| S:228 E:236 ||| JJ
oncologists  ||| S:236 E:248 ||| JJ
caring  ||| S:248 E:255 ||| NN
for  ||| S:255 E:259 ||| IN
patients  ||| S:259 E:268 ||| NNS
with  ||| S:268 E:273 ||| IN
lung  ||| S:273 E:278 ||| NN
or  ||| S:278 E:281 ||| CC
colorectal  ||| S:281 E:292 ||| JJ
cancer ||| S:292 E:298 ||| NN
.  ||| S:298 E:300 ||| .
We  ||| S:300 E:303 ||| PRP
surveyed  ||| S:303 E:312 ||| VBD
medical  ||| S:312 E:320 ||| JJ
oncologists  ||| S:320 E:332 ||| JJ
caring  ||| S:332 E:339 ||| NN
for  ||| S:339 E:343 ||| IN
patients  ||| S:343 E:352 ||| NNS
with  ||| S:352 E:357 ||| IN
lung  ||| S:357 E:362 ||| NN
or  ||| S:362 E:365 ||| CC
colorectal  ||| S:365 E:376 ||| JJ
cancer  ||| S:376 E:383 ||| NN
in  ||| S:383 E:386 ||| IN
the  ||| S:386 E:390 ||| DT
Cancer  ||| S:390 E:397 ||| NNP
Care  ||| S:397 E:402 ||| NNP
Outcomes  ||| S:402 E:411 ||| NNP
Research  ||| S:411 E:420 ||| NNP
and  ||| S:420 E:424 ||| CC
Surveillance  ||| S:424 E:437 ||| NNP
Consortium  ||| S:437 E:448 ||| NNP
from  ||| S:448 E:453 ||| IN
2012  ||| S:453 E:458 ||| CD
to  ||| S:458 E:461 ||| TO
2013  ||| S:461 E:466 ||| CD
( ||| S:466 E:467 ||| -LRB-
participation  ||| S:467 E:481 ||| NN
rate ||| S:481 E:485 ||| NN
,  ||| S:485 E:487 ||| ,
53 ||| S:487 E:489 ||| CD
% ||| S:489 E:490 ||| NN
) ||| S:490 E:491 ||| -RRB-
.  ||| S:491 E:493 ||| .
Oncologists  ||| S:493 E:505 ||| NNP
reported  ||| S:505 E:514 ||| VBD
experiences  ||| S:514 E:526 ||| VBN
with  ||| S:526 E:531 ||| IN
shortages  ||| S:531 E:541 ||| NNS
of  ||| S:541 E:544 ||| IN
leucovorin ||| S:544 E:554 ||| NN
,  ||| S:554 E:556 ||| ,
fluorouracil ||| S:556 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
dexamethasone ||| S:570 E:583 ||| NN
,  ||| S:583 E:585 ||| ,
cyanocobalamin ||| S:585 E:599 ||| NN
,  ||| S:599 E:601 ||| ,
paclitaxel ||| S:601 E:611 ||| NN
,  ||| S:611 E:613 ||| ,
cisplatin ||| S:613 E:622 ||| NN
,  ||| S:622 E:624 ||| ,
and  ||| S:624 E:628 ||| CC
etoposide  ||| S:628 E:638 ||| NN
in  ||| S:638 E:641 ||| IN
the  ||| S:641 E:645 ||| DT
prior  ||| S:645 E:651 ||| JJ
year  ||| S:651 E:656 ||| NN
and  ||| S:656 E:660 ||| CC
whether  ||| S:660 E:668 ||| IN
they  ||| S:668 E:673 ||| PRP
had  ||| S:673 E:677 ||| VBD
used  ||| S:677 E:682 ||| VBN
a  ||| S:682 E:684 ||| DT
less-effective  ||| S:684 E:699 ||| JJ
alternative  ||| S:699 E:711 ||| NN
because  ||| S:711 E:719 ||| IN
of  ||| S:719 E:722 ||| IN
a  ||| S:722 E:724 ||| DT
shortage ||| S:724 E:732 ||| NN
.  ||| S:732 E:734 ||| .
We  ||| S:734 E:737 ||| PRP
used  ||| S:737 E:742 ||| VBD
multivariable  ||| S:742 E:756 ||| JJ
logistic  ||| S:756 E:765 ||| JJ
regression  ||| S:765 E:776 ||| NN
to  ||| S:776 E:779 ||| TO
assess  ||| S:779 E:786 ||| VB
for  ||| S:786 E:790 ||| IN
associations  ||| S:790 E:803 ||| NNS
between  ||| S:803 E:811 ||| IN
physician  ||| S:811 E:821 ||| NN
or  ||| S:821 E:824 ||| CC
practice  ||| S:824 E:833 ||| NN
characteristics  ||| S:833 E:849 ||| NNS
and  ||| S:849 E:853 ||| CC
encountering  ||| S:853 E:866 ||| JJ
shortages ||| S:866 E:875 ||| NNS
.  ||| S:875 E:877 ||| .
Among  ||| S:877 E:883 ||| IN
330  ||| S:883 E:887 ||| CD
respondents ||| S:887 E:898 ||| NNS
,  ||| S:898 E:900 ||| ,
74 ||| S:900 E:902 ||| CD
%  ||| S:902 E:904 ||| NN
reported  ||| S:904 E:913 ||| VBD
experiences  ||| S:913 E:925 ||| VBN
with  ||| S:925 E:930 ||| IN
a  ||| S:930 E:932 ||| DT
shortage  ||| S:932 E:941 ||| NN
of  ||| S:941 E:944 ||| IN
at  ||| S:944 E:947 ||| IN
least  ||| S:947 E:953 ||| JJS
one  ||| S:953 E:957 ||| CD
drug  ||| S:957 E:962 ||| NN
in  ||| S:962 E:965 ||| IN
our  ||| S:965 E:969 ||| PRP$
survey ||| S:969 E:975 ||| NN
,  ||| S:975 E:977 ||| ,
and  ||| S:977 E:981 ||| CC
28 ||| S:981 E:983 ||| CD
%  ||| S:983 E:985 ||| NN
reported  ||| S:985 E:994 ||| VBD
using  ||| S:994 E:1000 ||| VBG
a  ||| S:1000 E:1002 ||| DT
less-effective  ||| S:1002 E:1017 ||| JJ
alternative  ||| S:1017 E:1029 ||| NN
because  ||| S:1029 E:1037 ||| IN
of  ||| S:1037 E:1040 ||| IN
a  ||| S:1040 E:1042 ||| DT
shortage ||| S:1042 E:1050 ||| NN
.  ||| S:1050 E:1052 ||| .
Although  ||| S:1052 E:1061 ||| IN
physician  ||| S:1061 E:1071 ||| JJ
demographic  ||| S:1071 E:1083 ||| JJ
characteristics  ||| S:1083 E:1099 ||| NNS
did  ||| S:1099 E:1103 ||| VBD
not  ||| S:1103 E:1107 ||| RB
predict  ||| S:1107 E:1115 ||| VB
reports  ||| S:1115 E:1123 ||| NNS
of  ||| S:1123 E:1126 ||| IN
drug  ||| S:1126 E:1131 ||| NN
shortages ||| S:1131 E:1140 ||| NNS
,  ||| S:1140 E:1142 ||| ,
practice  ||| S:1142 E:1151 ||| NN
characteristics  ||| S:1151 E:1167 ||| NNS
did ||| S:1167 E:1170 ||| VBD
.  ||| S:1170 E:1172 ||| .
Veterans  ||| S:1172 E:1181 ||| NNP
Affairs  ||| S:1181 E:1189 ||| NNP
( ||| S:1189 E:1190 ||| -LRB-
VA ||| S:1190 E:1192 ||| NNP
)  ||| S:1192 E:1194 ||| -RRB-
oncologists  ||| S:1194 E:1206 ||| NN
were  ||| S:1206 E:1211 ||| VBD
less  ||| S:1211 E:1216 ||| RBR
likely  ||| S:1216 E:1223 ||| JJ
to  ||| S:1223 E:1226 ||| TO
report  ||| S:1226 E:1233 ||| VB
experiencing  ||| S:1233 E:1246 ||| VBG
any  ||| S:1246 E:1250 ||| DT
shortage  ||| S:1250 E:1259 ||| NN
than  ||| S:1259 E:1264 ||| IN
oncologists  ||| S:1264 E:1276 ||| NN
in  ||| S:1276 E:1279 ||| IN
single-specialty  ||| S:1279 E:1296 ||| JJ
group  ||| S:1296 E:1302 ||| NN
practice  ||| S:1302 E:1311 ||| NN
( ||| S:1311 E:1312 ||| -LRB-
odds  ||| S:1312 E:1317 ||| JJ
ratio  ||| S:1317 E:1323 ||| NN
[ ||| S:1323 E:1324 ||| -LRB-
OR ||| S:1324 E:1326 ||| NNP
] ||| S:1326 E:1327 ||| -RRB-
,  ||| S:1327 E:1329 ||| ,
0.4 ||| S:1329 E:1332 ||| CD
;  ||| S:1332 E:1334 ||| :
95 ||| S:1334 E:1336 ||| CD
%  ||| S:1336 E:1338 ||| NN
CI ||| S:1338 E:1340 ||| NNP
,  ||| S:1340 E:1342 ||| ,
0.2  ||| S:1342 E:1346 ||| CD
to  ||| S:1346 E:1349 ||| TO
0.9 ||| S:1349 E:1352 ||| CD
) ||| S:1352 E:1353 ||| -RRB-
.  ||| S:1353 E:1355 ||| .
The  ||| S:1355 E:1359 ||| DT
reported  ||| S:1359 E:1368 ||| JJ
use  ||| S:1368 E:1372 ||| NN
of  ||| S:1372 E:1375 ||| IN
a  ||| S:1375 E:1377 ||| DT
less  ||| S:1377 E:1382 ||| RBR
effective  ||| S:1382 E:1392 ||| JJ
alternative  ||| S:1392 E:1404 ||| NN
to  ||| S:1404 E:1407 ||| TO
any  ||| S:1407 E:1411 ||| DT
drug  ||| S:1411 E:1416 ||| NN
was  ||| S:1416 E:1420 ||| VBD
also  ||| S:1420 E:1425 ||| RB
less  ||| S:1425 E:1430 ||| RBR
common  ||| S:1430 E:1437 ||| JJ
among  ||| S:1437 E:1443 ||| IN
VA  ||| S:1443 E:1446 ||| NNP
oncologists  ||| S:1446 E:1458 ||| NNS
( ||| S:1458 E:1459 ||| -LRB-
OR ||| S:1459 E:1461 ||| NNP
,  ||| S:1461 E:1463 ||| ,
0.3 ||| S:1463 E:1466 ||| CD
;  ||| S:1466 E:1468 ||| :
95 ||| S:1468 E:1470 ||| CD
%  ||| S:1470 E:1472 ||| NN
CI ||| S:1472 E:1474 ||| NNP
,  ||| S:1474 E:1476 ||| ,
0.1  ||| S:1476 E:1480 ||| CD
to  ||| S:1480 E:1483 ||| TO
0.9 ||| S:1483 E:1486 ||| CD
)  ||| S:1486 E:1488 ||| -RRB-
and  ||| S:1488 E:1492 ||| CC
oncologists  ||| S:1492 E:1504 ||| VB
affiliated  ||| S:1504 E:1515 ||| VBN
with  ||| S:1515 E:1520 ||| IN
health  ||| S:1520 E:1527 ||| NN
maintenance  ||| S:1527 E:1539 ||| NN
organizations  ||| S:1539 E:1553 ||| NNS
( ||| S:1553 E:1554 ||| -LRB-
OR ||| S:1554 E:1556 ||| NNP
,  ||| S:1556 E:1558 ||| ,
0.4 ||| S:1558 E:1561 ||| CD
;  ||| S:1561 E:1563 ||| :
95 ||| S:1563 E:1565 ||| CD
%  ||| S:1565 E:1567 ||| NN
CI ||| S:1567 E:1569 ||| NNP
,  ||| S:1569 E:1571 ||| ,
0.2  ||| S:1571 E:1575 ||| CD
to  ||| S:1575 E:1578 ||| TO
0.9 ||| S:1578 E:1581 ||| CD
)  ||| S:1581 E:1583 ||| -RRB-
compared  ||| S:1583 E:1592 ||| VBN
with  ||| S:1592 E:1597 ||| IN
physicians  ||| S:1597 E:1608 ||| NNS
in  ||| S:1608 E:1611 ||| IN
single-specialty  ||| S:1611 E:1628 ||| JJ
groups ||| S:1628 E:1634 ||| NNS
.  ||| S:1634 E:1636 ||| .
Most  ||| S:1636 E:1641 ||| RBS
oncologists  ||| S:1641 E:1653 ||| JJ
encountered  ||| S:1653 E:1665 ||| JJ
drug  ||| S:1665 E:1670 ||| NN
shortages  ||| S:1670 E:1680 ||| NNS
in  ||| S:1680 E:1683 ||| IN
the  ||| S:1683 E:1687 ||| DT
year  ||| S:1687 E:1692 ||| NN
before  ||| S:1692 E:1699 ||| IN
our  ||| S:1699 E:1703 ||| PRP$
survey ||| S:1703 E:1709 ||| NN
,  ||| S:1709 E:1711 ||| ,
but  ||| S:1711 E:1715 ||| CC
experiences  ||| S:1715 E:1727 ||| NNS
with  ||| S:1727 E:1732 ||| IN
shortages  ||| S:1732 E:1742 ||| NNS
varied  ||| S:1742 E:1749 ||| VBN
with  ||| S:1749 E:1754 ||| IN
practice  ||| S:1754 E:1763 ||| NN
structure ||| S:1763 E:1772 ||| NN
.  ||| S:1772 E:1774 ||| .
Further  ||| S:1774 E:1782 ||| JJ
research  ||| S:1782 E:1791 ||| NN
is  ||| S:1791 E:1794 ||| VBZ
needed  ||| S:1794 E:1801 ||| VBN
to  ||| S:1801 E:1804 ||| TO
quantitatively  ||| S:1804 E:1819 ||| VB
assess  ||| S:1819 E:1826 ||| VB
the  ||| S:1826 E:1830 ||| DT
impact  ||| S:1830 E:1837 ||| NN
of  ||| S:1837 E:1840 ||| IN
drug  ||| S:1840 E:1845 ||| NN
shortages  ||| S:1845 E:1855 ||| NNS
on  ||| S:1855 E:1858 ||| IN
patients  ||| S:1858 E:1867 ||| NNS
and  ||| S:1867 E:1871 ||| CC
evaluate  ||| S:1871 E:1880 ||| VB
various  ||| S:1880 E:1888 ||| JJ
strategies  ||| S:1888 E:1899 ||| NNS
for  ||| S:1899 E:1903 ||| IN
managing  ||| S:1903 E:1912 ||| VBG
them ||| S:1912 E:1916 ||| PRP
.  ||| S:1916 E:1918 ||| .
